Many patients may no longer have the option to be reimbursed for taking the lipid lowering drug ezetimibe to achieve lower LDL-C targets if the PBS accepts recommendations to clamp down on costly overprescribing. The number of patients prescribed ezetimibe outside of PBS restriction criteria could be as high 53% the Pharmaceutical Benefits Advisory Committee ...
PBAC moves to restrict subsidised use of ezetimibe to high risk patients
By Sunalie Silva
26 May 2017